Glythera, an oncology spin-out of Bath University, has presented new data supporting the efficiency of its technology to fight cancer.
The spin-out’s PermaLink technology is able to address several issues currently faced by biotech companies wanting to exploit antibody drug conjugates. These conjugates are a new kind of drugs for targeted therapy, which blocks specific molecules responsible for tumour growth and metastasis. The other two available oncological treatments are hormonal therapy and chemotherapy.
PermaLink was recently granted a patent in…
